AstraZeneca booth at AACR 2026
Biotech

AZ ‘very confident’ in homegrown ADCs despite dropping 2 assets

AstraZeneca executives told Fierce they are “very confident” in their in-house ADC pipeline despite scrapping two underperforming candidates.
James Waldron Jul 27, 2026 5:26am
a lot of scissors

Amgen sheds around 40 staffers as struggles mount

Jul 24, 2026 4:45pm
A chessboard with blocks that read MA

Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug

Jul 27, 2026 6:08am
Oak Tree Hill Sky

RA Capital launches Oak Hill Bio onto the Nasdaq via SPAC

Jul 27, 2026 3:25pm
Comedy and tragedy masks on red curtain background

MapLight shares sink on mixed ph. 2 schizophrenia readout

Jul 27, 2026 11:37am
bedroom sleep

Apnimed aspires for up to $160M IPO as sleep apnea launch nears

Jul 27, 2026 11:30am
More News

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Jul 27, 2026 10:08am

Gossamer and Chiesi pull the plug on PAH drug collaboration

Jul 27, 2026 10:03am
Fierce Pharma

Legend Biotech CEO resigns; search underway for replacement

Jul 27, 2026 9:32am

Fierce Biotech Layoff Tracker 2026: Amgen, Clinuvel & more

Jul 24, 2026 4:00pm